Spravato Insurance Coverage in Nevada in 2026

Spravato (esketamine) became the first FDA-approved nasal spray for treatment-resistant depression in 2019. In 2026, insurance coverage for Spravato in Nevada has matured — but it remains uneven, subject to prior authorization requirements, and heavily dependent on which plan you carry. This post explains what Nevada patients can realistically expect from their coverage.

This is educational information about insurance processes, not medical or legal advice.

What Spravato Is and Why It Has Different Coverage Than IV Ketamine

Spravato is a nasal spray formulation of esketamine — a close chemical relative of ketamine. The FDA approved it specifically for treatment-resistant depression (ICD-10 F32.9, F33.2) in adults who have not responded to at least two adequate antidepressant trials, and for major depressive disorder with acute suicidal ideation. Detailed approval information is available at FDA.gov.

This FDA-specific indication is the key reason Spravato has better insurance coverage than off-label IV ketamine infusions. Insurers generally require an FDA-approved indication before they will consider a drug for formulary coverage. Off-label IV ketamine lacks that FDA approval for psychiatric indications, which is why it remains largely out-of-pocket for most patients.

Spravato is dispensed in a certified clinical setting. After the patient self-administers the nasal spray, a mandatory two-hour on-site monitoring period follows each session. Sessions are typically twice weekly for four weeks, then weekly, then every one to two weeks for maintenance.

Nevada Medicaid Coverage for Spravato

Nevada Medicaid, administered by the Nevada Department of Health and Human Services, covers Spravato for eligible members when specific clinical criteria are met. As of 2026, those criteria generally include:

A diagnosis of treatment-resistant depression (F32.9 or F33.2)
Documentation that at least two adequate antidepressant trials have failed (adequate meaning appropriate dose and duration)
A prior authorization submitted by the treating clinician

Nevada Medicaid’s pharmacy and medical benefits are administered in part through managed care organizations. The specific plan a member is enrolled in affects the exact prior authorization form and clinical criteria. Contact your Nevada Medicaid managed care plan directly — or ask your prescribing clinician to initiate the prior authorization — to understand the specific requirements.

Nevada Check Up, the CHIP program for children, is a separate program and Spravato’s indication is in adults; this is unlikely to be a relevant coverage pathway for most patients.

Coverage determinations can be appealed. If your initial prior authorization is denied, your clinician can submit supporting documentation — including the ICD-10 diagnosis code, prior treatment history, and clinical rationale — as part of a formal appeal.

Commercial Insurance: Anthem Blue Cross Nevada and Other Major Plans

Anthem Blue Cross Nevada is one of the largest commercial insurers in Nevada, and Spravato coverage is available on many Anthem plans as of 2026. The general requirements mirror what most large commercial insurers ask for:

A confirmed diagnosis of treatment-resistant depression supported by ICD-10 codes (F32.9, F33.2)
Documentation of prior antidepressant treatment failures (step therapy)
Treatment by a psychiatrist or other qualifying clinician
Prior authorization approved before the first session

Anthem typically requires that Spravato be administered at a REMS-certified site, which is also a legal requirement, so this aligns with clinical reality.

UnitedHealthcare Nevada and Aetna plans in Nevada follow comparable prior authorization frameworks. Coverage is more consistent on employer-sponsored plans than on individual market plans, where coverage may be narrower.

The drug itself — esketamine — is typically covered under the medical benefit (not the pharmacy benefit) when administered in a clinical setting, billed alongside the office visit using standard E/M codes (CPT 99213 or 99214) for the monitoring component.

If your Nevada commercial plan denies a Spravato prior authorization, the appeals process is a realistic option. Your clinician’s documentation of treatment history is critical to a successful appeal.

Practical Steps for Nevada Patients Seeking Coverage

If you are in Nevada and pursuing Spravato coverage through your insurer, here is a practical sequence:

Confirm your diagnosis with your treating clinician. Spravato requires a documented treatment-resistant depression diagnosis and a record of prior treatment attempts.
Ask your prescribing clinician to initiate a prior authorization with your insurer. This is typically handled by the clinic, not the patient.
Confirm the dispensing site is REMS-certified. This is a requirement for coverage under most payers and a legal requirement regardless.
Get the cost breakdown in writing. Even with insurance coverage, out-of-pocket costs for the office visit and monitoring time can vary. Ask the clinic for a written cost estimate that distinguishes drug costs from facility/monitoring costs.
Ask about the Spravato manufacturer patient assistance program. Janssen (the manufacturer) maintains a patient assistance program that may reduce out-of-pocket costs for commercially insured or uninsured patients who qualify.
Understand the maintenance schedule. Coverage criteria often apply per-phase (induction vs. maintenance). Confirm your plan covers both phases.

For guidance on navigating your specific Nevada insurer’s prior authorization process, contact us — we can point you toward clinics experienced with your plan.

What About IV Ketamine Coverage in Nevada?

Off-label IV ketamine infusions do not have an FDA-approved psychiatric indication, and as a result, they are not covered by Nevada Medicaid or most Nevada commercial plans as of 2026. The evaluation and management visits associated with treatment (CPT 99213/99214) and any psychiatric intake (CPT 90791) may be separately billable to insurance, but the infusion drug and administration costs are generally out-of-pocket.

Some Nevada ketamine clinics offer financing arrangements or sliding-scale fees. SAMHSA’s treatment locator at findtreatment.gov can help identify publicly funded mental health resources if cost is a barrier.

This content is for educational purposes only and does not constitute medical advice. Consult a licensed clinician about your specific situation.

Drafted by AI and reviewed by our editorial team. Last updated 2026-05-30.